Tag: Beckley Psytech - Psychedelic Alpha

Access exclusive insights, data and interviews with Pα+: learn more and subscribe today.

Read more about the article Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited

Beckley Psytech Strengthens Pipeline and Development Team With Acquisition of Eleusis Therapeutics Limited

Post published:October 24, 2022
Post category:Press Release

Read more about the article Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT

Beckley Psytech Announces Dosing of First Healthy Volunteers in Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of Second Innovative Formulation of 5-MeO-DMT

Post published:April 5, 2022
Post category:Press Release

Read more about the article Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for Treatment Resistant Depression Phase 2 Trials

Beckley Psytech Announces First Cohort of Psychotherapists Have Begun Training for Treatment Resistant Depression Phase 2 Trials

Post published:January 24, 2022
Post category:Press Release

Read more about the article Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT

Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial Assessing Safety and Tolerability of Intranasal 5-MeO-DMT

Post published:October 25, 2021
Post category:Press Release

Read more about the article Beckley Psytech announces first patient has received low-dose psilocybin in world-first clinical trial for rare headache disorder

Beckley Psytech announces first patient has received low-dose psilocybin in world-first clinical trial for rare headache disorder

Post published:September 14, 2021
Post category:Press Release

Read more about the article Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs

Beckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs

Post published:August 16, 2021
Post category:Press Release

Read more about the article Beckley Psytech partners with Fluence to create psychedelic therapy training programme

Beckley Psytech partners with Fluence to create psychedelic therapy training programme

Post published:April 20, 2021
Post category:Press Release

Read more about the article Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

Post published:April 13, 2021
Post category:Press Release

Read more about the article Beckley Psytech appoints ex-pharma CEO as Chief Operating Officer

Beckley Psytech appoints ex-pharma CEO as Chief Operating Officer

Post published:February 22, 2021
Post category:Press Release

Read more about the article UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

UK Regulators Approve Beckley Psytech Study of Psilocybin for Debilitating Headache Condition

Post published:January 27, 2021
Post category:Analysis News

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.